Table 5.
Comparison of OPA results in adults after pneumococcal vaccination
| Study
|
Miernyk et al. [48]
|
Jackson et al. [47]
|
de Roux et al. [45]
|
Musher et al. [49]
|
Frenck et al. [50]
|
Scott et al. [46]
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Target population
|
Adults, 55–70 years
|
Adultsa, 70–79 years
|
Adults, ≥70 years
|
Adultsb
|
Adults, 50–59 years
|
Adults, 18–49 years
|
|||||||
| Vaccine (Dosage) | PPV23 (0.5 mL) | PCV7 (0.5 mL) | PPV23 (0.5 mL) | PCV7 (0.5 mL) | PCV7 (1.0 mL) | PPV23 (0.5 mL) | PCV7 (0.5 mL) | PPV23 (0.5 mL) | PCV7 (0.5 mL) | PCV13 (0.5 mL) | PPV23 (0.5 mL) | PCV13 (0.5 mL) | |
|
|
|
|
|
|
|
|
|||||||
| OPA Titer by Serotype | 1 | 16 (4–256) | 4 (4–64) | - | - | - | - | - | - | - | 264 | 244 (123–486) | 467 (193–1,126) |
|
|
|
|
|
|
|
||||||||
| 3 | - | - | - | - | - | - | - | - | - | 78 | 13 (9–19) | 35 (19–64) | |
|
|
|
|
|
|
|
||||||||
| 4 | 96 (4–1,024) | 128 (4–1,024) | 45 (16–127) | 39 (13–110) | 106 (37–308) | 663 (454–971) | 1,457 (997–2,130) | - | - | 2,203 | 2,353 (1,553–3,564) | 2,580 (1,727–3,856) | |
|
|
|
|
|
|
|
||||||||
| 5 | - | - | - | - | - | - | - | - | - | 204 | 323 (117–887) | 489 (161–1,483) | |
|
|
|
|
|
|
|
||||||||
| 6A | - | - | - | - | - | - | - | - | - | 3,157 | 140 (43–464) | 2,702 (1,148–6,360) | |
|
|
|
|
|
|
|
||||||||
| 6B | 192 (32–1,024) | 512 (4–2,048) | 35 (15–84) | 27 (10–74) | 48 (19–125) | 809 (553–2,284) | 1,351 (938–1,946) | 159 | 135 | 3,215 | 1,867 (677–5,148) | 5,161 (254–10,453) | |
|
|
|
|
|
|
|
||||||||
| 7F | - | - | - | - | - | - | - | - | - | 2,691 | 3,251 (1,767–5,982) | 2,964 (1,553–5,659) | |
|
|
|
|
|
|
|
||||||||
| 9V | - | - | 17 (8–36) | 39 (18–86) | 32 (13–79) | 985 (710–1,366) | 2,915 (2,142–3,967) | - | - | 1,749 | 4,705 (2,066–1,0718) | 10,809 (5,762–20,277) | |
|
|
|
|
|
|
|
||||||||
| 14 | 384 (16–2,048) | 128 (4–2,048) | 259 (92–730) | 186 (68–515) | 235 (95–581) | 1,011 (639–1,598) | 2,397 (1,606–3,579) | 565 | 379 | 1,554 | 8,579 (5,772–12,754) | 9,855 (5,570–17,437) | |
|
|
|
|
|
|
|
||||||||
| 18C | - | - | 135 (65–281) | 119 (54–263) | 195 (89–426) | 465 (314–688) | 1,318 (919–1,889) | - | - | 1,978 | 741 (198–2,776) | 2,464 (1,051–5,775) | |
|
|
|
|
|
|
|
||||||||
| 19A | - | - | - | - | - | - | - | - | - | 1,022 | 562 (198–1,597) | 741 (416–1,321) | |
|
|
|
|
|
|
|
||||||||
| 19F | 512 (4–1,024) | 1024 (4–2,048) | 77 (37–158) | 50 (25–102) | 80 (40–160) | 203 (136–302) | 182 (121–273) | 54 | 39 | 625 | 708 (383–1,306) | 1,351 (629–2,904) | |
|
|
|
|
|
|
|
||||||||
| 23F | - | - | 168 (67–418) | 235 (91–611) | 106 (42–271) | 302 (206–444) | 1,309 (862–1,990) | 51 | 200 | 483 | 588 (328–1,055) | 3,566 (1,330–9,559) | |
Note. Results are expressed as: Median (Range) for Miernyk et al; GMT (95% CI) for Jackson et al, de Roux et al, and Scott et al; GMT for Musher et al. and Frenck et al.
a
Previous PPV23 recipients
b
Adults who recovered from pneumococcal pneumonia
OPA, opsonophagocytosis assay; GMC, geometric mean concentration; GMT, geometric mean titer (calculated from the reciprocal of the individual titers); CI, confidence interval; -, not reported